Sign Up Today and Learn More About D2M Biotherapeutics Stock
Invest in or calculate the value of your shares in D2M Biotherapeutics or other pre-IPO companies through EquityZen's platform.
D2M Biotherapeutics Stock (DTMB)
D2M Biotherapeutics focuses on the development of novel immunotherapeutics.
About D2M Biotherapeutics Stock
Founded
2019
Industries
Science and Engineering, Health Care, Biotechnology
D2M Biotherapeutics Press Mentions
Stay in the know about the latest news on D2M Biotherapeutics
Nan Bing on LinkedIn: D2M Biotherapeutics Announces First Patient Dosed in A Phase 1 Study… | 21 comments
linkedin • Jul 04, 2024
D2M Biotherapeutics Announces First Patient Dosed in A Phase 1 Study Evaluating DM919, a Novel MICA/B Antibody ...
prnewswire • May 23, 2024
/C O R R E C T I O N -- D2M Biotherapeutics, Inc./
finance • May 04, 2024
D2M Biotherapeutics Management
Leadership team at D2M Biotherapeutics
Founder and CEO
Nan Bing
Join now and verify your accreditation status to gain access to:
- D2M Biotherapeutics current valuation
- D2M Biotherapeutics stock price
- Available deals in D2M Biotherapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in D2M Biotherapeutics stock?
Accredited investors can buy pre-IPO stock in companies like D2M Biotherapeutics through EquityZen funds. These investments are made available by existing D2M Biotherapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell D2M Biotherapeutics stock?
Shareholders can sell their D2M Biotherapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
